Definitive Healthcare Corp

Definitive Healthcare Corp. engages in the provision of healthcare commercial intelligence. Its solution offers information on healthcare providers and their activities to help the customers optimize from product development to go-to-market planning, sales, and marketing execution. The company was founded by Jason Kranzt in February 2011 and is headquartered in Framingham, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Definitive Healthcare reports robust Q4 performance amidst industry challenges

Definitive Healthcare's Q4 2022 performance reflects strong revenue growth and profitability, driven by strategic acquisitions and product innovations, despite economic headwinds.
Challenges such as extended deal cycles and macroeconomic impacts require adaptive strategies, while opportunities in data matching, client growth, and market expansion offer avenues for future success.
The company's focus on cost management, sales enhancements, and long-term growth in the healthcare data market positions it well for sustained performance and industry leadership.
Guidance for Q1 2023 underscores financial stability and growth potential, signaling a proactive approach to navigating challenges and seizing opportunities in the evolving healthcare landscape.

Definitive Healthcare Corp reports solid Q1 results amidst growth strategies

Definitive Healthcare Corp (DH) delivered solid Q1 results amidst challenges, with a focus on enhancing data capabilities and strategic M&A for future growth.
While facing higher churn and margin impacts, the company remains resilient, with stable pricing and a proactive approach to driving performance improvements.
Opportunities lie in acquisitions, cross-selling to existing clients, and maintaining a strong market position through innovation and client value creation.

Definitive Healthcare reports strong Q2 earnings, eyes AI opportunities

Definitive Healthcare's Q2 performance showcased revenue growth, EBITDA margin, and strategic acquisitions, despite workforce reductions and customer declines.
The company's strengths lie in tech investments, market share gains, and cross-sell opportunities, while challenges include workforce reductions and economic uncertainties.
Opportunities in AI advancements, long-term market prospects, and strategic investments position Definitive Healthcare for sustained growth and client value creation.

Definitive Healthcare Corp excels in Q3 amidst market challenges

Definitive Healthcare Corp's Q3 showcased strong financial performance, customer wins, and a focus on innovation despite market challenges.
The company's resilience, marketing effectiveness, and strategies to address churn position it well for future growth and success.
With a commitment to product development, customer engagement, and market leadership, Definitive Healthcare Corp navigates tough market conditions with adaptability.

Definitive Healthcare posts solid Q4 results, eyes growth opportunities in 2024

Definitive Healthcare's Q4 2023 performance was strong, with revenue growth, margin maintenance, and client base expansion.
The company's strategic focus on product investments, customer retention, and innovation positions it well for growth in 2024.
Challenges in the life sciences segment and high M&A valuations are being addressed through strategic initiatives and market positioning.
Opportunities in data asset investment, margin growth, and strong demand present avenues for continued success and expansion.

Definitive Healthcare reports mixed Q1 results, eyes growth opportunities

Definitive Healthcare's Q1 2024 Earnings Call showcased a resilient performance amidst challenges, with a focus on operational excellence and product innovation. Despite facing macroeconomic headwinds and restructuring disruptions, the company remains optimistic about long-term opportunities, driven by improving macro conditions and strategic initiatives.

Definitive Healthcare reports Q2 revenue growth, addresses sales challenges

Definitive Healthcare's Q2 2024 earnings call highlighted mixed performance, with a focus on addressing sales challenges and enhancing operational efficiency. CEO Coop emphasized growth, profitability, and strategic changes to drive shareholder value.

Definitive Healthcare reports Q3 results, plans for growth and efficiency

Definitive Healthcare's Q3 performance showed resilience despite revenue and EBITDA declines, with a strategic focus on simplification and customer success.
While facing challenges like high churn rates, the company aims for future growth through new product offerings and customer expansion.
Opportunities lie in operational efficiency improvements, share buyback program expansion, and strategic product integration for enhanced value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acquisition broadens Definitive Healthcare's suite of healthcare commercial intelligence solutions with new data, analytics, and visualization tools tailor-built for the provider market Acquisition broadens Definitive Healthcare's suite of healthcare commercial intelligence solutions with new data, analytics, and visualization tools tailor-built for the provider market

Definitive Healthcare acquires Populi

FRAMINGHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2023.

Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2023

Neogen

Patterson Companies

Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.

3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates

Definitive Healthcare Corp. (DH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Definitive Healthcare Corp. (DH) Beat Estimates Again in Its Next Earnings Report?

FRAMINGHAM, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced selected preliminary financial results for the quarter ended June 30, 2023.

Definitive Healthcare Reports Preliminary Financial Results for Second Quarter Fiscal Year 2023, Reaffirms Full Year Guidance for Revenue and Adjusted EBITDA, and Announces Restatement of Previously Issued Financials

FRAMINGHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its second quarter ended June 30, 2023, on Thursday, August 3, 2023 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its Second Quarter 2023 Financial Results Conference Call and Webcast

Augmedix

Clover Health Investments

Zacks Medical Info Systems industry stocks like Definitive Healthcare (DH), Clover Health Investments (CLOV) and Augmedix (AUGX) are expected to gain from new normal trends.

3 Medical Info Systems Stocks to Consider From a Prospering Industry

New enhancements include a 5% increase in all-payor medical claims data, new intelligence on behavioral health, and a 50% increase in healthcare executive data New enhancements include a 5% increase in all-payor medical claims data, new intelligence on behavioral health, and a 50% increase in healthcare executive data

Definitive Healthcare expands the Atlas Dataset

Definitive Healthcare Corp. is a leader in the healthcare commercial intelligence market, providing comprehensive data and insights for the industry with a potential market opportunity of $10 billion. The company uses Microsoft Azure infrastructure and DataBricks technology to manage its 20 terabytes of raw data, including 300 million patient profiles and 2 million healthcare providers/facilities. The stock is currently trading at an attractive valuation, trading at an EV/sales multiple of 6.5x.

Definitive Healthcare: Leading The Healthcare Commercial Intelligence Market

FRAMINGHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will present at two upcoming conferences: the Stifel 2023 Cross Sector Insight Conference in Boston, MA and the 43rd Annual William Blair Growth Stock Conference in Chicago, IL.

Definitive Healthcare to Present at the Stifel 2023 Cross Sector Insight Conference and the 43rd Annual William Blair Growth Stock Conference

First annual report highlights Definitive Healthcare's successful efforts related to culture, governance, and the environment First annual report highlights Definitive Healthcare's successful efforts related to culture, governance, and the environment

Definitive Healthcare publishes 2022 Sustainability Report

FRAMINGHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Robert Musslewhite, and its Chief Financial Officer, Rick Booth, will present at the 51st Annual J.P. Morgan Global Technology, Media and Communications Conference.

Definitive Healthcare to Present at the 51st Annual J.P. Morgan Global Technology, Media and Communications Conference

Definitive Healthcare Corp. (NASDAQ:DH ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Matt Ruderman – Chief Legal Officer Robert Musslewhite – Chief Executive Officer Jason Krantz – Founder and Executive Chairman Rick Booth – Chief Financial Officer Conference Call Participants Jared Haase – William Blair Matt Shea – Needham & Co. Craig Hettenbach – Morgan Stanley Joe Vruwink – Baird David Grossman – Stifel Allen Lutz – Bank of America Johnathan McCary – Raymond James Jonathan Yong – Credit Suisse Operator Greetings and welcome to the Definitive Healthcare First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Definitive Healthcare Corp. (DH) Q1 2023 Earnings Call Transcript

Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago.

Definitive Healthcare Corp. (DH) Q1 Earnings and Revenues Surpass Estimates

Definitive Healthcare Corp. (DH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Definitive Healthcare Corp. (DH) Reports Next Week: What You Should Expect

FRAMINGHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its first quarter ended March 31, 2023 financial results will be released on Thursday, May 4, 2023, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its First Quarter 2023 Financial Results Conference Call and Webcast

Joint customers can integrate data from Definitive Healthcare's Atlas Dataset in the Snowflake Data Cloud Joint customers can integrate data from Definitive Healthcare's Atlas Dataset in the Snowflake Data Cloud

Definitive Healthcare brings healthcare commercial intelligence to Snowflake Marketplace

AngioDynamics

Casella Waste Systems

Enviva Partners

Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.

4 Toxic Stocks That Are Detrimental to Your Portfolio's Health

CoStar Group

Montauk Renewables

Westrock Coffee Holdings LLC

Similar to identifying stocks with growth potential, pinpointing toxic stocks and discarding them at the right time is the key to avoid losses. CSGP, DH, MNTK and WEST are few toxic stocks you should dump now.

4 Toxic Stocks That You Should Eliminate From Your Portfolio

FRAMINGHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Financial Officer, Rick Booth, will present at the Raymond James 2023 Institutional Investors Conference.

Definitive Healthcare to Present at the Raymond James 2023 Institutional Investors Conference

The consensus price target hints at a 29.8% upside potential for Definitive Healthcare Corp. (DH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Definitive Healthcare Corp. (DH)? Wall Street Analysts Think 29.75%

Definitive Healthcare Corp. (NASDAQ:DH ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Matt Ruderman - General Counsel Robert Musslewhite - CEO Jason Krantz - Chairman Rick Booth - CFO Conference Call Participants David Grossman - Stifel Craig Hettenbach - Morgan Stanley Jacob Staffel - Goldman Sachs Matt Shea - Needham Ryan Shanahan - Canaccord Genuity Glen Santangelo - Jefferies Brian Peterson - Raymond James Anne Samuel - JPMorgan Allen Lutz - Bank of America Operator Ladies and gentlemen, greetings, and welcome to the Definitive Healthcare Fourth Quarter 2022 Earnings Conference Call. At this time, all participant lines are in a listen only mode.

Definitive Healthcare Corp. (DH) Q4 2022 Earnings Call Transcript

Fourth quarter revenue grew 31% year-over-year to $60.6 million  Full year 2022 revenue grew 34% to $222.7 million

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2022

FRAMINGHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its fourth quarter and full year ended December 31, 2022 financial results will be released on Thursday, February 23, 2023, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast

Includes reference & affiliation data, all-payor & prescription claims, and medical experts to help clients analyze the healthcare market from nearly any vantage point Includes reference & affiliation data, all-payor & prescription claims, and medical experts to help clients analyze the healthcare market from nearly any vantage point

News for Definitive Healthcare Corp Stock (DH)